Abstract:The estrogen receptor α (ERα) is a clinically validated target for the treatment of estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. However, resistance to early line endocrine treatments due to mutations of the ESR1 gene encoding ERα is associated with poor prognosis and remains an area of unmet clinical need. ERα degradation using heterobifunctional degraders has emerged as a promising approach to tackle endocrine resistance through proteasome mediated degradation of the receptor. Here, we present the preclinical results for the development candidate, PVTX-321, an ERα heterobifunctional degrader. PVTX-321 is a rapid and potent ER heterobifunctional degrader as well as a full ERα antagonist. Both properties translate into potent antiproliferative activity across multiple ER+ breast cancer cell lines bearing either wild-type or clinically relevant ERα mutations (E380Q, Y537S and D538G). PVTX-321 demonstrates favorable oral bioavailability across different species and effectively induces dose-dependent degradation of ERα in vivo. Moreover, PVTX-321 achieves tumor regression as an oral agent at 10 mg/kg in MCF-7 mouse xenograft model. Furthermore, PVTX-321 possesses excellent in vitro and in vivo safety profiles and warrants further development for the treatment of ER+/HER2- breast cancer. Citation Format: Courtney G. Havens, Guozhang Xu, Cass Lowenstein, Debangshu Samanta, Brian Vidal, Elham Behshad, Rakesh Nagilla, Mike Russell, Peter Orth, Winston Wu, Larry Jolivette, Scott Priestley, Helai Mohammad, Zhihua Sui. Discovery and characterization of PVTX-321, an estrogen receptor heterobifunctional degrader [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6047.

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Discovery of ERD-12310A As an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor Α (Erα)

Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer

Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα)

Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer

Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery

Abstract LB179: Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer

Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer

Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models

Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer

Abstract 6047: Discovery and characterization of PVTX-321, an estrogen receptor heterobifunctional degrader

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway

New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives

A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant

PROTAC Degrader of Estrogen Receptor Α Targeting DNA-Binding Domain in Breast Cancer.

Discovery of ARD-2051 As a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

Strategies Toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.